Cue Biopharma, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CUE research report →
About the company
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical enterprise focused on creating biological therapies. Its central objective is the precise manipulation of the human immune system to address a spectrum of severe conditions, such as various cancers, chronic infectious diseases, and autoimmune disorders.
- CEO
- Lucinda Warren
- IPO
- 2018
- Employees
- 41
- HQ
- Boston, MA, US
Price Chart
- Market Cap
- $74.27M
- P/E
- -5.12
- P/S
- 2.27
- P/B
- 6.29
- EV/EBITDA
- -3.87
- Div Yield
- 0.00%
- Gross Margin
- 99.76%
- Op Margin
- -59.83%
- Net Margin
- -59.65%
- ROE
- -98.30%
- ROIC
- -78.19%
- Revenue
- $27.47M · 195.75%
- Net Income
- $-26,602,000 · 34.60%
- EPS
- $-8.40 · 61.11%
- Op Income
- $-26,521,000
- FCF YoY
- 39.93%
- 52W High
- $41.42
- 52W Low
- $4.98
- 50D MA
- $25.45
- 200D MA
- $17.19
- Beta
- 2.46
- Avg Volume
- 765.32K
Get TickerSpark's AI analysis on CUE
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 1, 26 | Meluzio Michael Vincent | other | 0 |
| Jun 1, 26 | Ray Sumita | other | 0 |
| Jun 1, 26 | Ray Sumita | other | 109,179 |
| May 30, 26 | Camardo Daniel A. | other | 1,626 |
| May 30, 26 | Camardo Daniel A. | other | 0 |
| Jun 1, 26 | Lin Shao-Lee | buy | 90,906 |
| Jun 1, 26 | Lin Shao-Lee | buy | 45,453 |
| May 30, 26 | Meehan Viola Mong | other | 1,626 |
| May 30, 26 | Meehan Viola Mong | other | 0 |
| Apr 30, 26 | Lin Shao-Lee | other | 0 |
Our CUE coverage
Recent articles, reports, and earnings notes.
No research on CUE yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CUE report →Similar companies
Peers in the same neighborhood.